Tracers / [177Lu]Lu-Rituximab
[177Lu]Lu-Rituximab
Also written as [Lu-177]Lu-Rituximab; Lu-177-Rituximab
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- —
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated anti-CD20 monoclonal antibody radioimmunoconjugate (rituximab)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | SPE | — | 95% | p-SCN-Bn-DOTA | 23256748 2013 Curr Radiopharm The antibodies tetulomab and rituximab were first labeled with p-SCN-Bn-DOTA dissolved in 0.005M HCl. |
Need this precursor?We can point you to suppliers for [177Lu]Lu-Rituximab, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 23256748: 'the backbone substituted chelator p-SCN-Bn-DOTA (tetraxetan)'.